Stockscreener 앱 받기
7.3499
9.17%
-0.7201
전일 마감가:
$8.07
열려 있는:
$8.04
하루 거래량:
231.85K
Relative Volume:
0.85
시가총액:
$365.54M
수익:
$36.90M
순이익/손실:
$-166.28M
주가수익비율:
-2.234
EPS:
-3.29
순현금흐름:
$-203.53M
1주 성능:
-9.73%
1개월 성능:
-12.43%
6개월 성능:
-21.18%
1년 성능:
-67.72%
1일 변동 폭
$7.26
$8.11
1주일 범위
$7.26
$9.08
52주 변동 폭
$6.10
$25.39
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
명칭
Bicycle Therapeutics Plc Adr
전화
011441223261503
주소
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
BCYC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCYC
Bicycle Therapeutics Plc Adr
|
7.33 | 559.80M | 36.90M | -166.28M | -203.53M | -3.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.71 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.32 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.20 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
821.58 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.03 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-31 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-08 | 개시 | Stephens | Equal-Weight |
| 2024-09-06 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-07 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-09-11 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2022-08-31 | 개시 | Cowen | Outperform |
| 2022-07-28 | 개시 | Barclays | Overweight |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-04-13 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2022-04-07 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-02-14 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 개시 | SVB Leerink | Outperform |
| 2021-12-09 | 개시 | Needham | Buy |
| 2021-09-30 | 개시 | B. Riley Securities | Buy |
| 2021-04-20 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-06-12 | 개시 | Oppenheimer | Outperform |
| 2020-04-17 | 개시 | H.C. Wainwright | Buy |
| 2019-11-14 | 개시 | ROTH Capital | Buy |
| 2019-09-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-06-17 | 개시 | Canaccord Genuity | Buy |
| 2019-06-17 | 개시 | Goldman | Neutral |
| 2019-06-17 | 개시 | Jefferies | Buy |
| 2019-06-17 | 개시 | Piper Jaffray | Overweight |
모두보기
Bicycle Therapeutics Plc Adr 주식(BCYC)의 최신 뉴스
Pinnacle Associates Ltd. Sells 42,325 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Analysts Set Expectations for BCYC Q1 Earnings - MarketBeat
EBITDA per share of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView
Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap DownHere's Why - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Up 9.8% on Earnings Beat - MarketBeat
Bicycle Therapeutics stock price target raised to $12 from $10 at Citizens By Investing.com - Investing.com South Africa
RBC Capital downgrades Bicycle Therapeutics stock on delayed pipeline progress By Investing.com - Investing.com South Africa
Bicycle Therapeutics earnings beat by $0.23, revenue topped estimates - Investing.com South Africa
Bicycle Therapeutics PLC Sponsored ADR $BCYC Position Boosted by Tybourne Capital Management HK Ltd. - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Up 5.2%Here's Why - MarketBeat
100,291 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Acquired by Janney Montgomery Scott LLC - Defense World
Global X MLP & Energy Infrastructure ETF $MLPX Holdings Boosted by Janney Montgomery Scott LLC - Defense World
Bicycle Therapeutics (NASDAQ:BCYC) Receives “Sell (D-)” Rating from Weiss Ratings - Defense World
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Analyzing Fractyl Health (NASDAQ:GUTS) & Plus Therapeutics (NASDAQ:PSTV) - Defense World
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Bicycle Therapeutics (NASDAQ:BCYC) Trading Up 10.5%What's Next? - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 3,231 Shares - MarketBeat
Insider Selling: Bicycle Therapeutics (NASDAQ:BCYC) CEO Sells 2,263 Shares of Stock - MarketBeat
Bicycle Therapeutics Sees Unusually Large Options Volume (NASDAQ:BCYC) - Defense World
Stock Traders Purchase High Volume of Bicycle Therapeutics Call Options (NASDAQ:BCYC) - MarketBeat
Goldman Sachs Group Inc. Takes Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC - Defense World
Bicycle Therapeutics (NASDAQ:BCYC) Trading Up 7.8%Here's Why - MarketBeat
126,062 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Acquired by Acadian Asset Management LLC - MarketBeat
Analysts Set Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Price Target at $22.22 - MarketBeat
126,062 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Bought by Acadian Asset Management LLC - Defense World
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
3 Stocks To Buy Under $10 That Could Triple From Here - Barchart.com
Cubist Systematic Strategies LLC Sells 2,650 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - Defense World
Bicycle Therapeutics appoints oncology veterans Dansey and Hoppenot to board - Investing.com India
Caption Management LLC Sells 81,517 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Armistice Capital LLC Has $22.69 Million Holdings in Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Long Focus Capital Management LLC Acquires 750,661 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Bicycle Therapeutics PLC Sponsored ADR $BCYC Stock Holdings Cut by Tybourne Capital Management HK Ltd. - MarketBeat
Bicycle Toxin Conjugates Clinical Trials FDA Approval Proprietary Technology Cancer Drugs Report 2025 - GlobeNewswire Inc.
Candriam S.C.A. Acquires 117,331 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Analysts’ Weekly Ratings Updates for Bicycle Therapeutics (BCYC) - Defense World
Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress - Investing.com
Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress By Investing.com - Investing.com South Africa
Bicycle Therapeutics (NASDAQ:BCYC) Given New $13.00 Price Target at Morgan Stanley - Defense World
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results - Placera.se
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock? - MSN
Rice Biotech Launch Pad adds TPG Life Sciences’ Carolyn Ng to board - Investing.com
Should I buy Bicycle Therapeutics (BCYC) - Zacks Investment Research
Coursera (NYSE:COUR) Sees Strong Trading Volume on Analyst Upgrade - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Teacher Retirement System of Texas - Defense World
Principal Financial Group Inc. Boosts Stock Position in Schneider National, Inc. (NYSE:SNDR) - Defense World
Principal Financial Group Inc. Purchases 1,695 Shares of Monarch Casino & Resort, Inc. (NASDAQ:MCRI) - Defense World
Teacher Retirement System of Texas Has $465,000 Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Teacher Retirement System of Texas Sells 1,266 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Teacher Retirement System of Texas Has $534,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Bicycle Therapeutics Plc Adr (BCYC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.33%
0.05%
자본화:
|
볼륨(24시간):